KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash & Equivalents (2016 - 2026)

Halozyme Therapeutics has reported Cash & Equivalents over the past 17 years, most recently at $309.7 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 75.67% to $309.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $309.7 million through Mar 2026, up 75.67% year-over-year, with the annual reading at $133.8 million for FY2025, 15.51% up from the prior year.
  • Cash & Equivalents was $309.7 million for Q1 2026 at Halozyme Therapeutics, up from $133.8 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $419.7 million in Q3 2025 and troughed at $61.9 million in Q2 2025.
  • The 5-year median for Cash & Equivalents is $154.3 million (2024), against an average of $177.9 million.
  • Year-over-year, Cash & Equivalents crashed 79.66% in 2022 and then soared 171.95% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $234.2 million in 2022, then plummeted by 49.46% to $118.4 million in 2023, then fell by 2.13% to $115.8 million in 2024, then increased by 15.51% to $133.8 million in 2025, then skyrocketed by 131.47% to $309.7 million in 2026.
  • Per Business Quant, the three most recent readings for HALO's Cash & Equivalents are $309.7 million (Q1 2026), $133.8 million (Q4 2025), and $419.7 million (Q3 2025).